Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OMER Omeros

Market Closed 02-20 16:00:00 EST

12.04

+0.03

+0.25%

盘后12.04

+0.000.00%

19:48 EST

High12.22	Low11.73	Vol1.01M
Open11.86	D1 Closing12.01	Amplitude4.08%
Mkt Cap853.64M	Tradable Cap777.19M	Total Shares70.90M
T/O12.10M	T/O Rate1.56%	Tradable Shares64.55M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OMER","market":"US","secType":"STK","nameCN":"Omeros","latestPrice":12.04,"timestamp":1771621200000,"preClose":12.01,"halted":0,"volume":1007423,"hourTrading":{"tag":"盘后","latestPrice":12.04,"preClose":12.04,"latestTime":"19:48 EST","volume":17093,"amount":205859.8729,"timestamp":1771634903568,"change":0,"changeRate":0,"amplitude":0.006653},"delay":0,"changeRate":0.0024979184013321698,"floatShares":64550800,"shares":70900459,"eps":-2.009792,"marketStatus":"Market Closed","change":0.03,"latestTime":"02-20 16:00:00 EST","open":11.86,"high":12.22,"low":11.73,"amount":12098192.170727,"amplitude":0.040799,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.009792,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1771837200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1254974400000,"exchange":"NASDAQ","adjPreClose":12.01,"preHourTrading":{"tag":"盘前","latestPrice":11.93,"preClose":12.01,"latestTime":"09:24 EST","volume":342,"amount":4089.224232,"timestamp":1771597499015,"change":-0.08,"changeRate":-0.006661,"amplitude":0.008143},"postHourTrading":{"tag":"盘后","latestPrice":12.04,"preClose":12.04,"latestTime":"19:48 EST","volume":17093,"amount":205859.8729,"timestamp":1771634903568,"change":0,"changeRate":0,"amplitude":0.006653},"volumeRatio":1.2683100686837718,"impliedVol":0.5984,"impliedVolPercentile":0.1514},"requestUrl":"/m/hq/s/OMER","defaultTab":"news","newsList":[{"id":"2612694754","title":"Omeros: YARTEMLEA Cash Flows Funding High-Upside OncotoX-AML Pipeline, Supporting Buy Rating and $40 Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2612694754","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612694754?lang=en_us&edition=fundamental","pubTime":"2026-02-18 01:05","pubTimestamp":1771347922,"startTime":"0","endTime":"0","summary":"In a report released today, Brandon Folkes from H.C. Wainwright reiterated a Buy rating on Omeros, with a price target of $40.00. Brandon Folkes ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/omeros-yartemlea-cash-flows-funding-high-upside-oncotox-aml-pipeline-supporting-buy-rating-and-40-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/omeros-yartemlea-cash-flows-funding-high-upside-oncotox-aml-pipeline-supporting-buy-rating-and-40-target-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2612468837","title":"Omeros announces completion of nonhuman primates OncotoX-AML study","url":"https://stock-news.laohu8.com/highlight/detail?id=2612468837","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612468837?lang=en_us&edition=fundamental","pubTime":"2026-02-17 22:15","pubTimestamp":1771337738,"startTime":"0","endTime":"0","summary":"Omeros (OMER) announced the completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer thera...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-announces-completion-of-nonhuman-primates-oncotox-aml-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-announces-completion-of-nonhuman-primates-oncotox-aml-study-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2612724457","title":"Omeros Reports Successful Primate Study of OncotoX-AML for Leukemia Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2612724457","media":"Reuters","labels":["productRelease","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612724457?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:45","pubTimestamp":1771335918,"startTime":"0","endTime":"0","summary":"Omeros Corporation announced the successful completion of an initial nonhuman primate study evaluating its OncotoX-AML therapeutic platform for acute myeloid leukemia . The study demonstrated a marked, selective, and reversible reduction in myeloid progenitor cells, with OncotoX-AML being well tolerated and showing no significant safety signals. In preclinical murine-human xenograft models, OncotoX-AML also showed superior efficacy compared to standard-of-care treatments. The results from these studies have already been presented, and Omeros plans to initiate IND-enabling studies to advance OncotoX-AML toward clinical trials, targeting a first-in-human trial in late 2027.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL3zNJkg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2606368657","title":"Omeros Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2606368657","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606368657?lang=en_us&edition=fundamental","pubTime":"2026-01-28 00:03","pubTimestamp":1769529780,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 27, 2026 11:03 ET (16:03 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2606738060","title":"Omeros Begins Commercial Sales of Stem Cell Complication Drug Yartemlea","url":"https://stock-news.laohu8.com/highlight/detail?id=2606738060","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606738060?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:52","pubTimestamp":1769525528,"startTime":"0","endTime":"0","summary":"Omeros  said Tuesday that it has begun commercial sales of Yartemlea following initial shipments to distributors and early use by transplant centers in the US.Financial details related to early sales were not provided.The company said that orders were received and filled last week, and that the drug is now being given to both adult and pediatric patients with transplant-associated thrombotic microangiopathy, including those treated in hospitals and outpatient settings.Omeros said Yartemlea received US Food and Drug Administration approval last month and is cleared for patients aged two years and older.Omeros said an application seeking European approval for Yartemlea is under review by regulators, with a decision expected in mid-2026.Price: 11.56, Change: +0.03, Percent Change: +0.22","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OMER"],"gpt_icon":0},{"id":"2606780443","title":"Omeros announces first commercial sales of Yartemlea","url":"https://stock-news.laohu8.com/highlight/detail?id=2606780443","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606780443?lang=en_us&edition=fundamental","pubTime":"2026-01-27 22:20","pubTimestamp":1769523624,"startTime":"0","endTime":"0","summary":"Omeros (OMER) Corporation announced that the first commercial shipments of Yartemlea to its distributors were completed last week, with orders from...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-announces-first-commercial-sales-of-yartemlea-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-announces-first-commercial-sales-of-yartemlea-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2605040665","title":"OMER S.p.A.: Sector Tailwinds, Solid Fundamentals and Undemanding Valuation Support Buy Rating and €5.5 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2605040665","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605040665?lang=en_us&edition=fundamental","pubTime":"2026-01-23 22:26","pubTimestamp":1769178381,"startTime":"0","endTime":"0","summary":"Analyst Alessio Olmi from TP ICAP MIDCAP maintained a Buy rating on OMER S.p.a. and keeping the price target at €5.50. Alessio Olmi has given his B...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/omer-s-p-a-sector-tailwinds-solid-fundamentals-and-undemanding-valuation-support-buy-rating-and-e5-5-target-price-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/omer-s-p-a-sector-tailwinds-solid-fundamentals-and-undemanding-valuation-support-buy-rating-and-e5-5-target-price-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2603149624","title":"Top Omeros Executive Makes a Major Move With Company Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2603149624","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603149624?lang=en_us&edition=fundamental","pubTime":"2026-01-15 10:02","pubTimestamp":1768442551,"startTime":"0","endTime":"0","summary":"New insider activity at Omeros ( ($OMER) ) has taken place on January 14, 2026. Omeros has reported an insider stock sale by its VP, Finance & CAO,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/top-omeros-executive-makes-a-major-move-with-company-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/top-omeros-executive-makes-a-major-move-with-company-stock-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2603647077","title":"Omeros VP Finance & CAO David J. Borges Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2603647077","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603647077?lang=en_us&edition=fundamental","pubTime":"2026-01-15 06:25","pubTimestamp":1768429553,"startTime":"0","endTime":"0","summary":"David J. Borges, Vice President, Finance & Chief Accounting Officer of Omeros Corporation, reported a disposal of common shares of Omeros Corporation. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Omeros Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 14, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL5x8lTh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Omeros VP Finance & CAO David J. Borges Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2601836043","title":"Omeros (OMER) Receives a Buy from WBB Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2601836043","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601836043?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:15","pubTimestamp":1767881750,"startTime":"0","endTime":"0","summary":"In a report released today, Stephen Brozak from WBB Securities maintained a Buy rating on Omeros, with a price target of $55.00. According to TipRa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/omeros-omer-receives-a-buy-from-wbb-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/omeros-omer-receives-a-buy-from-wbb-securities-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","OMER"],"gpt_icon":0},{"id":"2601364007","title":"Omeros Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364007","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364007?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:19","pubTimestamp":1767878340,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/OMER/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 08, 2026 08:19 ET (13:19 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OMER"],"gpt_icon":0},{"id":"2601369150","title":"Balanced Risk/Reward and Gradual Yartemlea Ramp Justify Hold Rating on Omeros","url":"https://stock-news.laohu8.com/highlight/detail?id=2601369150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601369150?lang=en_us&edition=fundamental","pubTime":"2026-01-08 20:15","pubTimestamp":1767874551,"startTime":"0","endTime":"0","summary":"Needham analyst Serge Belanger has maintained their neutral stance on OMER stock, giving a Hold rating on December 30. Serge Belanger has given his...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-and-gradual-yartemlea-ramp-justify-hold-rating-on-omeros-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/balanced-risk-reward-and-gradual-yartemlea-ramp-justify-hold-rating-on-omeros-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2601336301","title":"Omeros price target raised to $40 from $20 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2601336301","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601336301?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:11","pubTimestamp":1767870695,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Brandon Folkes raised the firm’s price target on Omeros (OMER) to $40 from $20 and keeps a Buy rating on the shares. The fi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/omeros-price-target-raised-to-40-from-20-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/omeros-price-target-raised-to-40-from-20-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMER"],"gpt_icon":0},{"id":"2601363931","title":"Omeros Corporation : H.c. Wainwright Raises Target Price to $40 From $20","url":"https://stock-news.laohu8.com/highlight/detail?id=2601363931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601363931?lang=en_us&edition=fundamental","pubTime":"2026-01-08 19:06","pubTimestamp":1767870395,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nAZN4RSH1A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OMER","BK4007"],"gpt_icon":0},{"id":"2600657340","title":"Exchange-Traded Funds, Equity Futures Higher Ahead of First Trading Day of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600657340","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600657340?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:46","pubTimestamp":1767361595,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.6%, and the actively traded Invesco QQQ Trust (QQQ) advanced 1% in Friday's premarket activity ahead of the first trading da","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLK","IVV","PMR","XRT","XLF","SOC.AU","SPY","VDC","VHT","XLI","RTH.AU","IYJ","UNG","BETH","EEM",".DJI","SOC","EQR","IYW","VHT.AU","VIS","IYK","QQQ","XSD","FAZ","IGM","XLV","RTH","EXI","BITO","SOXX","FAS","IBB","XLY","XLE","IYH","OMER","XLP","IYE","BITF","SPY.AU","EETH"],"gpt_icon":1},{"id":"2600065161","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2600065161","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600065161?lang=en_us&edition=fundamental","pubTime":"2026-01-02 21:29","pubTimestamp":1767360585,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed premarket Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) up 0.1% and the iShares Biotechnology ETF (IBB) flat.Omeros (OMER) stock was up 4.4% premarket after closing the previous session with a 1.3% rise.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XLV","BK4550","XBI","STT","BK4585","IE00B3QW5Z07.USD","OMER","IE0034235188.USD","LU0061475181.USD","BK4581","LABU","FDN","IE00B64PRP62.GBP","BK4007","BK4588","LU1894683264.USD","LU1894683348.USD","BK4135","IBB","LU1883839398.USD","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2600708537","title":"The Year-End 2025 Biotech Rally And What It Means For 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2600708537","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2600708537?lang=en_us&edition=fundamental","pubTime":"2025-12-31 23:54","pubTimestamp":1767196440,"startTime":"0","endTime":"0","summary":"Biotechnology stocks are wrapping up 2025 on a high note, bouncing back from a rocky start to deliver some of the year’s most impressive gains. What began as a sector weighed down by tariff fears and political noise has transformed into one of the market’s standout performers, powered by deal making, drug approvals, and breakthrough clinical results. The big question heading into 2026 is simple: can this momentum last?The performance metrics speak volumes. The iShares Biotechnology ETF  has climbed 29.51% year to date through December 29, while the State Street SPDR S&P Biotech ETF  has done even better with gains around 35.84%. The Nasdaq Biotechnology Index sits at 5,766.59, marking a 34% jump for the year.Regulatory wins provided another boost. The FDA greenlit 44 new therapies in 2025, with 26 approvals coming in the second half alone. December saw notable wins including Cytokinetics Incorporated’s  Myqorzo for a heart condition, marking the company’s first approval after 27 years ","market":"us","thumbnail":"/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["/next-assets/images/benzinga-post-card-placeholder.svg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/25/12/49650052/the-year-end-2025-biotech-rally-and-what-it-means-for-2026","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["USAW.SI","BK4532","IE00BBT3K403.USD","NQmain","IE00BJT1NW94.SGD","GPCR","SG9999014906.USD","IE0005OL40V9.USD","NVS","QID","IE00BVYPNW00.USD","LU1116320737.USD","IE00B1BXHZ80.USD","OMER","SQQQ","BK4505","QLD","ITCI","SG9999014880.SGD","JNJ","BK4581","VRNA","IBB","LU0823434740.USD","LU2430703178.SGD","MNQmain","LU2063271972.USD","LU1037948897.HKD","LU1935042991.SGD","EYPT","LU0471298694.HKD","IONS","TSYW.SI","MRK","TQQQ","MNPR","CYTK","LU0432979614.USD","PSQ","USJW.SI","LU2592432038.USD","NVIW.SI","PFE",".IXIC","LU0256863811.USD","RNA","LU2089984988.USD","LU0306807586.USD"],"gpt_icon":1},{"id":"2594494299","title":"Biohaven, Omeros And Other Big Stocks Moving Lower In Friday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2594494299","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594494299?lang=en_us&edition=fundamental","pubTime":"2025-12-26 21:03","pubTimestamp":1766754180,"startTime":"0","endTime":"0","summary":"U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Friday.Shares of Biohaven Ltd  fell sharply in pre-market trading after the company reported that its Phase 2 depression drug trial missed its primary endpoint.The biopharmaceutical company announced BHV-7000, an investigational drug for major depressive disorder, failed to achieve a reduction in depressive symptoms versus placebo in the six-week study, measured by the Montgomery sberg Depression Rating Scale.Biohaven shares dipped 14.3% to $9.27 in pre-market trading.Here are some other stocks moving lower in pre-market trading.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/26/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/26/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49592180/biohaven-omeros-and-other-big-stocks-moving-lower-in-fridays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49592180/biohaven-omeros-and-other-big-stocks-moving-lower-in-fridays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4007","BHVN","OMER","LU1093756325.SGD","BK4139","LU1093756168.USD"],"gpt_icon":0},{"id":"2594128665","title":"Nike, Omeros Corporation, Micron Technology, Intel And Dynavax Technologies: Why These 5 Stocks Are On Investors' Radars Today","url":"https://stock-news.laohu8.com/highlight/detail?id=2594128665","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594128665?lang=en_us&edition=fundamental","pubTime":"2025-12-25 09:49","pubTimestamp":1766627340,"startTime":"0","endTime":"0","summary":"The Dow Jones Industrial Average climbed 0.6% to 48,731.16, while the S&P 500 added 0.32% to close at 6,932.05.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/24/Stock-Market-Trading-Graph-And-Financial.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/24/Stock-Market-Trading-Graph-And-Financial.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/12/49588564/nike-omeros-corporation-micron-technology-intel-and-dynavax-technologies-why-these-5-stocks-are-on-investors-radars-today","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/12/49588564/nike-omeros-corporation-micron-technology-intel-and-dynavax-technologies-why-these-5-stocks-are-on-investors-radars-today","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["NKE","LU2211815571.USD","BK4579","BK4512","LU0097036916.USD","LU0310800379.SGD","BK4550","LU2360106780.USD","BK4141","BK4553","LU0128525929.USD","BK4529","LU0792757196.USD","BK4515","LU0321505439.SGD","BK4139","GB00BDT5M118.USD","BK4535","BK4588","LU0708994859.HKD","BK4146","IE00B19Z3B42.SGD","BK4543","LU1267930573.SGD","LU0786609619.USD","LU0274383776.USD","BK4612","LU1267930813.SGD","LU0056508442.USD","LU0082616367.USD","LU0029864427.USD","BK4566","BK4534","BK4602","LU0321505868.SGD","BK4007","LU1323610961.USD","LU2048586759.USD","LU0081259029.USD","BK4533","IE00B7SZLL34.SGD","OMER","LU2089985449.USD","BK4527","LU0642271901.SGD","LU2931357623.SGD","LU0157215616.USD","LU0203345920.USD","BK4581","IE00B19Z3581.USD","LU1366333091.USD","LU2148611432.USD","LU2543165471.USD","LU1852331112.SGD","LU1303367103.USD","BK4554","BK4211","BK4561","BK4605","LU1316542783.SGD","IE00BYQQ9H92.USD","BK4585","LU0889566641.SGD","BK4575","LU2250418816.HKD","DVAX","IE00BFXG0V08.USD","IE0002270589.USD","LU0127658192.USD","BK4558","LU2286300806.USD","INTC","LU0203347892.USD","BK4532","MU","LU0719512351.SGD","LU0823411888.USD","LU2098885051.SGD","04335"],"gpt_icon":1},{"id":"2594888632","title":"Analysts Are Neutral on Top Healthcare Stocks: Biohaven Ltd. (BHVN), Omeros (OMER)","url":"https://stock-news.laohu8.com/highlight/detail?id=2594888632","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594888632?lang=en_us&edition=fundamental","pubTime":"2025-12-25 05:40","pubTimestamp":1766612406,"startTime":"0","endTime":"0","summary":"Analysts fell to the sidelines weighing in on Biohaven Ltd. (BHVN – Research Report) and Omeros (OMER – Research Report) with neutral ratings, indi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-biohaven-ltd-bhvn-omeros-omer-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-neutral-on-top-healthcare-stocks-biohaven-ltd-bhvn-omeros-omer-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","OMER","XLV","BHVN"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.omeros.com","stockEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0033},{"period":"3month","weight":0.3574},{"period":"6month","weight":1.7364},{"period":"1year","weight":0.2529},{"period":"ytd","weight":-0.299}],"compareEarnings":[{"period":"1week","weight":0.0113},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0461},{"period":"6month","weight":0.0684},{"period":"1year","weight":0.1295},{"period":"ytd","weight":0.011}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.","yearOnYearQuotes":[{"month":1,"riseRate":0.352941,"avgChangeRate":-0.012739},{"month":2,"riseRate":0.588235,"avgChangeRate":0.056909},{"month":3,"riseRate":0.625,"avgChangeRate":0.097428},{"month":4,"riseRate":0.375,"avgChangeRate":-0.031657},{"month":5,"riseRate":0.375,"avgChangeRate":-0.032445},{"month":6,"riseRate":0.3125,"avgChangeRate":0.036171},{"month":7,"riseRate":0.4375,"avgChangeRate":0.065457},{"month":8,"riseRate":0.3125,"avgChangeRate":-0.029297},{"month":9,"riseRate":0.3125,"avgChangeRate":-0.001727},{"month":10,"riseRate":0.5,"avgChangeRate":-0.042054},{"month":11,"riseRate":0.647059,"avgChangeRate":0.236058},{"month":12,"riseRate":0.529412,"avgChangeRate":0.065706}],"exchange":"NASDAQ","name":"Omeros","nameEN":"Omeros"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Omeros,OMER,Omeros股票,Omeros股票老虎,Omeros股票老虎国际,Omeros行情,Omeros股票行情,Omeros股价,Omeros股市,Omeros股票价格,Omeros股票交易,Omeros股票购买,Omeros股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Omeros(OMER),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Omeros(OMER) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}